RxDoctor Payments DataLook up a doctor →

Michael Donovan, MD

Family Medicine · Saint Louis, MONPI 1669852448

Payments from drug & device makers

$77,915in general payments, 2019–2025

Across 845 payments — averaging $92.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$63K
  • Gilead$5K
  • Napo Pharmaceuticals Inc$866
  • Merck$808
  • Pfizer$700
  • AbbVie$679
  • plus $7K from 45 others

What the payments were for

  • Consulting fees$1,7502%
  • Speaking & faculty fees$50,08564%
  • Travel & lodging$8,74811%
  • Food & beverage$17,21722%
  • Education$1140%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$77,915 in reported general payments places this provider in the 95th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$37,550
Medicare patients
80
Services billed
2,160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala40$181,817
OzempicSemaglutide119$142,635
DovatoDolutegravir Sodium/Lamivudine17$52,114
DescovyEmtricitabine/Tenofov Alafenam18$49,816
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$47,258
JardianceEmpagliflozin41$38,507
TivicayDolutegravir Sodium14$36,081
PifeltroDoravirine14$29,083
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$26,524
EliquisApixaban24$25,363
MounjaroTirzepatide20$21,175
TrulicityDulaglutide13$14,118
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$14,063
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$10,090
FarxigaDapagliflozin Propanediol11$9,250

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$5,079$278,89170 claims
Novo NordiskOzempic$673$142,635119 claims
Viiv Healthcare CompanyDovato, Tivicay$62,963$88,19431 claims
Boehringer IngelheimJardiance, Combivent Respimat$158$44,08952 claims
GSKTrelegy Ellipta, Anoro Ellipta, Shingrix$148$42,66957 claims
Lilly USA, LLCMounjaro, Trulicity$453$35,29333 claims
PfizerEliquis, Abrysvo$700$29,33743 claims
MerckPifeltro$808$29,08314 claims
AstraZenecaBreztri Aerosphere, Farxiga$346$19,34027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →